EPLIN Polyclonal Antibody
Applications
Predicted Reactivity
| Overview | |
| Catalog # | bs-13086R-100uL |
| Product Name | EPLIN Polyclonal Antibody |
| Applications |
WB
ELISA
IHC-P
IHC-F
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Predicted Reactivity | Human, Mouse, Dog, Cow, Sheep, Horse, Rabbit |
| Specifications | |
| Conjugation | Unconjugated |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human EPLIN |
| Immunogen Range | 161-260/759 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target | |
| Gene ID | 51474 |
| Subcellular location | Cytoplasm, Cell membrane |
| Synonyms | 1110021C24Rik; Epithelial protein lost in neoplasm; Epithelial protein lost in neoplasm beta; EPLIN; FLJ38853; LIM domain and actin binding 1; LIM domain and actin binding protein 1; LIM domain and actin-binding protein 1; LIMA1; LIMA1_HUMAN; MGC131726; SREBP3; Sterol regulatory element binding protein 3. |
| Background | Epithelial protein lost in neoplasm (EPLIN) is a cytoskeleton-associated protein characterized by the presence of a single centrally located lin-11, isl-1 and mec-3 (LIM) domain. It also contains at least two Actin-binding domains, in which the C-terminal domain binds more effectively than the N-terminal domain. By binding Actin monomers and filaments, EPLIN is involved in regulation of the Actin cytoskeleton by increasing the number and size of Actin stress fibers, delaying filament nucleation, reducing formation of branched filaments and bundling of Actin filaments. It also inhibits membrane ruffling and Actin filament depolymerization. EPLIN is strongly expressed in placenta, kidney, pancreas, prostate, ovary, spleen and heart, and to a lesser degree in lung, liver, brain, skeletal muscle, thymus, testis and intestine. It is expressed as two isoforms, EPLIN- and EPLIN-_. Downregulation of EPLIN- expression may contribute to the motility of invasive tumor cells. |
| Application Dilution | |
| WB | 1:300-5000 |
| ELISA | 1:500-1000 |
| IHC-P | 1:200-400 |
| IHC-F | 1:100-500 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is EPLIN Polyclonal Antibody (bs-13086R) validated for, and at what dilution?
bs-13086R is validated for WB (1:300-5000); ELISA (1:500-1000); IHC-P (1:200-400); IHC-F (1:100-500); IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200); ICC (1:100-500). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
How should bs-13086R be stored?
Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. Storage buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise EPLIN Polyclonal Antibody (bs-13086R)?
KLH conjugated synthetic peptide derived from human EPLIN Immunogen range: 161-260/759.